NCT02353286

Brief Summary

Patients with either post-cholecystectomy bile leak or benign biliary stricture are recruited for endoscopic insertion of a biodegradable biliary stent. A follow-up of 12 months with repeated serum samples and magnetic resonance imaging is scheduled. The primary end points are feasibility of endoscopic insertion with the novel implantation device and stricture or leak resolution as well as clinical treatment success.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
14

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2014

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2014

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

January 16, 2015

Completed
17 days until next milestone

First Posted

Study publicly available on registry

February 2, 2015

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2017

Completed
Last Updated

May 14, 2018

Status Verified

May 1, 2018

Enrollment Period

3.7 years

First QC Date

January 16, 2015

Last Update Submit

May 7, 2018

Conditions

Keywords

Biodegradable stents, ERCP

Outcome Measures

Primary Outcomes (1)

  • Clinical treatment success of stricture or leakage, treatment failure rate measured by change in treatment protocol or unplanned interventions, radiologic stricture diameter in MRI, radiologic stent degradation in MRI

    Stent patency, unplanned admissions and interventions, signs of cholangitis during treatment assessed by repeated liver function tests, magnetic resonance imaging and interview. Change in stent diameter and gradual radiologic dissappearance due to degradation assessed by repeated MRI and liver function tests, stricture resolution assessed by repeated MRI and radiologic measurement of stricture width as well as liver function tests, leakage resolution assessed by disappearance of biliary fluid collection in MRI and liver function tests

    The follow-up of 12 months after stent implantation

Secondary Outcomes (2)

  • ERCP complications, late adverse events during stent therapy

    30 days from stent implantation, late adverse events up to 12 months

  • Technical success of stent insertion

    intraoperative

Study Arms (2)

Post-cholecystecomy bile leak

EXPERIMENTAL

Endoscopic insertion of biodegradable biliary stent

Device: Endoscopic insertion of biodegradable biliary stent

Benign biliary stricture

EXPERIMENTAL

Endoscopic insertion of biodegradable biliary stent

Device: Endoscopic insertion of biodegradable biliary stent

Interventions

Endoscopic insertion of biodegradable biliary stent

Also known as: Braided, self-expanding polydioxanone stent, Ella, Czech Rep
Benign biliary stricturePost-cholecystecomy bile leak

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • informed-consent patients with diagnosed or suspected post-cholecystectomy biliary leak or benign biliary stricture.

You may not qualify if:

  • Patients with contra-indications for magnetic resonance imaging (MRI) or surgically altered gastro-duodenal anatomy (e.g. roux-y-loop) are excluded from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tampere University Hospital, Dept. of Gastroenterology and Alimentary Tract Surgery

Tampere, 33521, Finland

Location

Related Publications (6)

  • Mauri G, Michelozzi C, Melchiorre F, Poretti D, Tramarin M, Pedicini V, Solbiati L, Cornalba G, Sconfienza LM. Biodegradable biliary stent implantation in the treatment of benign bilioplastic-refractory biliary strictures: preliminary experience. Eur Radiol. 2013 Dec;23(12):3304-10. doi: 10.1007/s00330-013-2947-2. Epub 2013 Jul 11.

    PMID: 23842947BACKGROUND
  • Laukkarinen J, Nordback I, Mikkonen J, Karkkainen P, Sand J. A novel biodegradable biliary stent in the endoscopic treatment of cystic-duct leakage after cholecystectomy. Gastrointest Endosc. 2007 Jun;65(7):1063-8. doi: 10.1016/j.gie.2006.11.059.

    PMID: 17531643BACKGROUND
  • Grolich T, Crha M, Novotny L, Kala Z, Hep A, Necas A, Hlavsa J, Mitas L, Misik J. Self-expandable biodegradable biliary stents in porcine model. J Surg Res. 2015 Feb;193(2):606-12. doi: 10.1016/j.jss.2014.08.006. Epub 2014 Aug 9.

    PMID: 25201575BACKGROUND
  • Lorenzo-Zuniga V, Moreno-de-Vega V, Marin I, Boix J. Biodegradable stents in gastrointestinal endoscopy. World J Gastroenterol. 2014 Mar 7;20(9):2212-7. doi: 10.3748/wjg.v20.i9.2212.

    PMID: 24605020BACKGROUND
  • Siiki A, Rinta-Kiikka I, Sand J, Laukkarinen J. A pilot study of endoscopically inserted biodegradable biliary stents in the treatment of benign biliary strictures and cystic duct leaks. Gastrointest Endosc. 2018 Apr;87(4):1132-1137. doi: 10.1016/j.gie.2017.10.042. Epub 2017 Nov 8.

  • Siiki A, Rinta-Kiikka I, Sand J, Laukkarinen J. Biodegradable biliary stent in the endoscopic treatment of cystic duct leak after cholecystectomy: the first case report and review of literature. J Laparoendosc Adv Surg Tech A. 2015 May;25(5):419-22. doi: 10.1089/lap.2015.0068. Epub 2015 Apr 8.

MeSH Terms

Conditions

Biliary Tract Diseases

Condition Hierarchy (Ancestors)

Digestive System Diseases

Study Officials

  • Johanna Laukkarinen, Md, PhD

    Dept. of Gastroenterology and Alimentary Tract Surgery

    STUDY DIRECTOR
  • Juhani Sand, Md, PhD

    Dept. of Gastroenterology and Alimentary Tract Surgery

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

January 16, 2015

First Posted

February 2, 2015

Study Start

May 1, 2014

Primary Completion

December 31, 2017

Study Completion

December 31, 2017

Last Updated

May 14, 2018

Record last verified: 2018-05

Data Sharing

IPD Sharing
Will not share

Locations